186 related articles for article (PubMed ID: 30306406)
1. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.
Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G
Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406
[TBL] [Abstract][Full Text] [Related]
2. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
3. Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.
Rydén A; Chen S; Flood E; Romero B; Grandy S
Patient; 2017 Aug; 10(4):475-487. PubMed ID: 28315192
[TBL] [Abstract][Full Text] [Related]
4. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
Fifer S; Rose J; Hamrosi KK; Swain D
BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
[TBL] [Abstract][Full Text] [Related]
5. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
[TBL] [Abstract][Full Text] [Related]
6. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
[TBL] [Abstract][Full Text] [Related]
7. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
8. Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment.
Ozdemir S; Baid D; Verghese NR; Lam AY; Lee PC; Lim AY; Zhu L; Ganguly S; Finkelstein EA; Goh SY
Value Health; 2020 Jul; 23(7):842-850. PubMed ID: 32762985
[TBL] [Abstract][Full Text] [Related]
9. An overview of new GLP-1 receptor agonists for type 2 diabetes.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
[TBL] [Abstract][Full Text] [Related]
10. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.
Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG
Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594
[TBL] [Abstract][Full Text] [Related]
11. A discrete choice experiment to understand preferences of patients with type 2 diabetes treated with injectable non-insulinic agents.
Darbà J; Ascanio M
Curr Med Res Opin; 2021 Jan; 37(1):37-43. PubMed ID: 33269944
[TBL] [Abstract][Full Text] [Related]
12. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.
Gelhorn HL; Bacci ED; Poon JL; Boye KS; Suzuki S; Babineaux SM
Patient Prefer Adherence; 2016; 10():1337-48. PubMed ID: 27524889
[TBL] [Abstract][Full Text] [Related]
13. [Patients' preferences in the medicamentous treatment of diabetes mellitus type 2: A systematic classification and meta-comparison of patient preference studies].
Mühlbacher AC; Kaczynski A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Apr; 58(4-5):452-66. PubMed ID: 25687713
[TBL] [Abstract][Full Text] [Related]
14. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.
Gelhorn HL; Poon JL; Davies EW; Paczkowski R; Curtis SE; Boye KS
Patient Prefer Adherence; 2015; 9():1611-22. PubMed ID: 26635470
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
[TBL] [Abstract][Full Text] [Related]
16. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin JA
Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
[TBL] [Abstract][Full Text] [Related]
20. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
Mühlbacher A; Bethge S
Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]